Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2016 Dec 13;7(50):82473-82481.
doi: 10.18632/oncotarget.12666.

Bevacizumab and wound-healing complications: a systematic review and meta-analysis of randomized controlled trials

Hongliang Zhang  1 , Zhenguang Huang  1 , Xiaoqin Zou  1 , Taotao Liu  1
Affiliations
Meta-Analysis

Bevacizumab and wound-healing complications: a systematic review and meta-analysis of randomized controlled trials

Hongliang Zhang et al. Oncotarget. .

Abstract

A meta-analysis was conducted to estimate the risk of wound-healing complications in patients who treated with neoadjuvant-adjuvant bevacizumab in various oncological indications. We searched PUBMED, EMBASE and the Cochrane Library through June 2016 to identify randomized controlled trials of bevacizumab and wound-healing complications. Seven RCTs studies involving 5,147 participants were included in the analysis. Compared with routine therapy, bevacizumab increased the incidence of wound-healing complications for various cancers. The pooled estimate of odds ratio (OR) was 2.32, and the 95 % confidence intervals (CI) was 1.43 to 3.75. (P < 0.001). Subgroup analyses revealed the similar result in colon carcinoma patients. In conclusion, bevacizumab increases the incidence of wound-healing complications for cancers especially for colon neoplasms patients. However, the adverse effect is not appeared in breast cancer, metastatic renal cell carcinoma, non-small-cell lung cancer and gastro-oesophageal adenocarcinoma. Due to the findings relying chiefly on data from single or two studies, hence, further research is required to assess the wound-healing complications risk of bevacizumab in each oncological indication.

Keywords: bevacizumab; meta-analysis; systematic review; wound-healing complications.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST

The authors have reported no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.

Figures

Figure 1
Figure 1. Selection process for the studies included in the meta-analysis
Figure 2
Figure 2
(A) Risk of bias summary; (B) Risk of bias graph
Figure 2
Figure 2
(A) Risk of bias summary; (B) Risk of bias graph
Figure 3
Figure 3. Incidence of wound-healing complications in bevacizumab versus control group
Figure 4
Figure 4. Subgroup analyses with different oncological indications
Figure 5
Figure 5. Subgroup analyses by operative status
See this image and copyright information in PMC

References

    1. Sharma K, Marcus JR. Bevacizumab and wound-healing complications: mechanisms of action, clinical evidence, and management recommendations for the plastic surgeon. Ann Plast Surg. 2013;71:434–440. - PubMed
    1. FDA Commissioner Removes Breast Cancer Indication from Avastin Label 2011 Nov 18; http://wwwfdagov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPati...
    1. Mansour J, Fields B, Macomson S, Rixe O. Significant anti-tumor effect of bevacizumab in treatment of pineal gland glioblastoma multiforme. Target Oncol. 2014;9:395–398. - PubMed
    1. Ellis LM. Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer. Semin Oncol. 2006;33:S1–7. - PubMed
    1. Nakahara T, Norberg SM, Shalinsky DR, Hu-Lowe DD, McDonald DM. Effect of inhibition of vascular endothelial growth factor signaling on distribution of extravasated antibodies in tumors. Cancer Res. 2006;66:1434–1445. - PubMed

LinkOut - more resources